ESMO 2026 | HANSOH PHARMA PRESENTS FIRST-IN-HUMAN PHASE 1 STUDY RESULTS OF SEZ6-TARGETING ANTIBODY-DRUG CONJUGATE HS-20108 IN PATIENTS WITH ADVANCED SOLID TUMORS
SHANGHAI, October 28, 2026 — Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma," 03692.HK) today announced that preliminary results from the Phase...
2026.10.28